85 records found.
Sep 05, 2018
Innovative Diagnostic Technology Playing Significant Role in Improving Detection for Better Cardiac Care
Sep 05, 2018
Correvio Reports Preliminary Data Collected from >2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study
Aug 28, 2018
Real-world Evidence From GARFIELD-AF Shows Superior Reduction in Mortality With Non-vitamin K Antagonists Oral Anticoagulants (NOACs) vs. Vitamin K Antagonists (VKAs) in Newly Diagnosed Atrial Fibrillation
Aug 24, 2018
Sotera Medical Secures Additional Funding
Aug 20, 2018
Thrombosis Research Institute (TRI) to Announce New Real-World Insights in Atrial Fibrillation at ESC Congress 2018
Aug 16, 2018
Dronedarone Promotes Cardiac Repair After a Heart Attack
Aug 16, 2018
Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients
Aug 14, 2018
FDA Approvals for Cardiac Electrophysiology Products Bright Spot in Healthcare Industry
Aug 14, 2018
Correvio Announces Brinavess® Selected as Potentially Eligible for Priority Review in China
Aug 13, 2018
Advanced Cardiac Therapeutics, Inc. Changes Name to EPIX Therapeutics, Inc.
Aug 08, 2018
Atrial Fibrillation Forecast In 19 Major Markets 2018-2028: Overview of the Classification and Patient Treatment Options for AF
Aug 07, 2018
Global Anticoagulants Market Expected to Reach $43,427 Million by 2025, Says Allied Market Research
Jul 16, 2018
Bardy Diagnostics(TM) Announces Additional Growth Capital Funding
Jul 10, 2018
Huntington Hospital Performs First WATCHMAN(TM) Left Atrial Appendage Closure to Treat Patients with Atrial Fibrillation
Jul 03, 2018
Atrial Fibrillation Devices 2018: Global Market Outlook to 2026 - Asia-Pacific is Expected to Exhibit Lucrative CAGR
Jun 29, 2018
Atrial Fibrillation Epidemiology: Global Industry Key Indicator Measures 2018-2026
Jun 22, 2018
GPB Capital Enters into $21 Million Debt Investment in CardioFocus®
Jun 11, 2018
Correvio Provides U.S. Regulatory Update for BRINAVESS
Jun 06, 2018
CardioNXT Announces Enrollment Completion of RADAR Clinical Trial
May 24, 2018
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation

Pages